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Abstract
Background: Oxidative stress may play a critical role in the vascular disease of end stage renal
failure and hemodialysis patients. Studies, analyzing either discrete analytes and antioxidant
substances, or the integrated total antioxidant activity of human plasma during hemodialysis, give
contradictory results.
Methods: Recently, we have introduced a new automated method for the determination of Total
Antioxidant Capacity (TAC) of human plasma. We have serially measured TAC and corrected TAC
(cTAC: after subtraction of the interactions due to endogenous uric acid, bilirubin and albumin) in
10 patients before the onset of the dialysis session, 10 min, 30 min, 1 h, 2 h and 3 h into the
procedure and after completion of the session.
Results: Our results indicate that TAC decreases, reaching minimum levels at 2 h. However,
corrected TAC increases with t1/2 of about 30 min. We then repeated the measurements in 65
patients undergoing dialysis with different filters (36 patients with ethylene vinyl alcohol copolymer
resin filter -Eval-, 23 patients with two polysulfone filters -10 with F6 and 13 with PSN140-, and 6
patients with hemophan filters). Three specimens were collected (0, 30, 240 min). The results of
this second group confirm our initial results, while no significant difference was observed using
either filter.
Conclusions: Our results are discussed under the point of view of possible mechanisms of
modification of endogenous antioxidants, and the interaction of lipid- and water-soluble
antioxidants.
Background
Hemodialysis represents a chronic stress status for its
recipients [1–3]. Although life salvaging, this procedure,
by the application of a modified circulation and the
forced passage of blood through a number of filters, acti-
vates endogenous inflammatory mechanisms and induces
chronic release of molecules resulting in an increased pro-
duction of reactive oxygen species [reviewed in [4,5]]. In
addition, uric acid, an endogenous metabolite eliminated
by hemodialysis, possesses significant antioxidant activity
[6], while fluctuations in other endogenous antioxidant
systems (plasma proteins, vitamins, etc) may lead to
major variations of the internal redox state [1,3,6–8].
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Circulation of oxidative molecules has been incriminated
in protein, carbohydrate and lipoprotein oxidation and
the generation of an increased arterial deposit, leading
ultimately to atherosclerosis [9,10]. Indeed, accelerated
development of atherogenesis and a number of vascular
episodes characterize patients with chronic renal failure
subjected to hemodialysis. In these patients oxidative
stress relies on three major components: (1) The dialysis
membrane, (2) the microbial contamination or pyrogen
content of the dialysate, (3) the possible prooxidant effect
of a number of metabolites, found at high concentrations
in the patients' plasma, including uric acid [11].
Cross-sectional studies of dialysis patients reveal that,
while traditional cardiovascular risk factors (hyperten-
sion, hypercholesterolemia) do not discriminate as well as
in the general population, markers of inflammation and
protein-calories malnutrition are highly correlated with
cardiovascular mortality. Interesting hypotheses have
been advanced, linked to the presence of oxidant stress
and its sequelae as a unifying concept of cardiovascular
disease in uremia [12]. A number of preventive strategies
have been recently introduced, during and after hemodi-
alysis, in order to counteract vascular disease. They
include administration of antioxidant vitamins, the use of
new biocompatible filters, presumably less immunogenic,
and the addition of vitamin, hormone or trace metals in
the patients' diet [1,2,13–23]. Nevertheless, although it is
generally accepted that oxidative stress may result from
dialysis therapy, no direct evidence exists confirming this
hypothesis. A number of reports, either measuring specific
analytes or enzymes [8,15,22,24–30], or estimating the
total antioxidant activity of the plasma [1–
3,6,7,9,26,29,31,32] give contradictory and non-conclu-
sive results.
Recently, we have introduced a new automated method
for the estimation of the plasma total antioxidant capacity
[33]. This method is based on the inhibition of oxidation
by plasma of an exogenously added marker (crocin) by an
added pro-oxidant (ABAP). In this respect, it integrates the
totality of circulating pro- and antioxidants, and gives a
rough (although accurate) estimate of the antioxidant sta-
tus of plasma at a given moment. In addition, we have
also corrected these results for a number of analytes,
directly affecting redox potential, thus introducing the
concept of "corrected antioxidant capacity". We have used
this assay in order to evaluate changes of the antioxidant
capacity of patients during a cycle of hemodialysis. Our
results indicate that, although the total antioxidant capac-
ity of hemodialyzed patients shows a decrease during the
procedure, the corrected antioxidant capacity increases,
indicating that counterbalancing mechanisms might
occur in human plasma, equilibrating the loss of uric acid
and other antioxidant metabolites.
Methods
Patients and controls
Ten patients dialyzed with an ethylene vinyl alcohol
copolymer resin (Eval) filter were analyzed. Seven sam-
ples were obtained from each patient, before the initiation
of dialysis, 30 min, 1, 2 and 3 hours into the session and
upon its completion. Sixty-five additional patients were
examined (32 males [age range 15–91 years, mean 62.7,
median 54.3 years] and 34 females [age range 26–88
years, mean 60.9, median 55.7 years]) and 56 volunteer
blood donors on a normal diet (38 males and 18 females,
age range 21–52 years, median 43.5 years). Polysulphone
dialysis membranes were used on 23 patients (F6: 10
patients and PSN140: 13 patients), hemophan mem-
branes on 6 (GFS 12 Plus) and ethylene vinyl alcohol
copolymer resin filters (Eval 1.6 or 1.3) on 36. Dialysis
age varied from 1 to 13.3 years (mean ± SE 6.0 ± 0.4 years,
median 5.2 years). No significant changes among the dif-
ferent groups were found. Renal failure was due to diabe-
tes (4 cases), polycystic kidney disease (8 cases), vasculitis
(4 cases), tuberculosis (1 case), chronic pyelonephritis (4
cases), interstitial nephritis (2 cases), chronic glomeru-
lonephritis (1 case), glomerulosclerosis (2 cases), hyper-
tension (2 cases), while 37 patients were refered to the
hospital with renal failure of unknown cause. All patients
received non-steroid antiinflammatory, Vitamin B, and
erythropoietin treatment. An informed consent was
obtained from all participants in the study. Three samples
(times 0, 30 and 240 min) were withdrawn from each
patient, while a single sample was obtained from each
blood donor on K3-EDTA. Plasma was immediately sepa-
rated by centrifugation (2000 g, 4°C), aliquoted and
stored at -80°C until assayed.
Determination of TAC
Plasma total antioxidant capacity (TAC) was measured on
an Olympus AU-600 chemistry analyzer using the TAC
kit, described previously [33] (Medicon SA, Gerakas,
Greece). Briefly, antioxidants in the sample inhibit the
oxidation (bleaching) of crocin from ABAP [2,2-Azobis-
(2-amidinopropane) dihydrochloride] to a degree that is
proportional to their concentration. The assay was per-
formed at 37°C in the following steps: 2 µl of sample, cal-
ibrator or control were mixed with 250 µl of crocin
reagent (R1) and incubated for 160 s. Subsequently, 250
µl of ABAP (R2) were added and the decrease in absorb-
ance at 450 nm was measured 256 s later. Values of TAC
were expressed as mmol/l of Trolox (a hydrophilic Vita-
min E derivative) equivalents. During the initial valida-
tion of the TAC assay [33] we found that uric acid,
bilirubin, and albumin accounted for 0.11, 0.11, and 0.01
mmol/mg of the antioxidant capacity, respectively. Sub-
traction of these interferences from the TAC value results
in the calculation of corrected TAC (cTAC), an estimate ofBMC Nephrology 2003, 4 http://www.biomedcentral.com/1471-2369/4/4
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the redox state attributed, mainly to circulating exogenous
antioxidants.
Routine clinical chemistry
Plasma uric acid, albumin, total and direct bilirubin, cho-
lesterol, HDL-cholesterol and triglycerides were deter-
mined on an Olympus AU-600 chemistry analyzer using
Olympus reagents provided by Medicon SA (Gerakas,
Greece), as follows: uric acid OSR6136, albumin
OSR6102, total bilirubin OSR6112, direct bilirubin
OSR6111, cholesterol OSR6116, HDL-cholesterol
OSR6187 and triglycerides OSR6133. LDL-cholesterol
was estimated by the Friedewald equation [LDL-choles-
terol = total cholesterol - (HDL-cholesterol + triglycerides/
5)], when triglyceride values were <400 mg/dl. For the
group of ten patients dialyzed with Eval membranes, a full
blood count (white blood cells, polymorphonuclear cells,
hemoglobin concentration, hematocrit value) accompa-
nied all serial measurements.
Statistics
Statistical analysis of data was performed by the use of the
SyStat v 10.0 program (SPSS Inc, Chicago, IL). Group dif-
ferences were compared at each data point using ANOVA
with the Bonferroni correction for small data sets. The
residual variance was used as a common estimate of the
Standard Error, and group means were therefore com-
pared by the Student's t-test. The Origin v 5.0 program
(MicroCal, Northampton, MA) was used for curve fitting.
Results
Metabolite variation during dialysis
Kinetics of a number of analytes during dialysis is pre-
sented in Figure 1. Uric acid concentrations decrease dur-
ing dialysis, following an exponential decay curve with t1/
2 of 104 min. Albumin, on the other hand presents a grad-
ual increase during dialysis, following an exponential
growth curve, with t1/2 of 101 ± 12.8 min, due to hemo-
concentration, as reflected by the hematocrit count. In
contrast, minor changes of bilirubin were found during
the dialysis cycle. Cholesterol on the other hand, as well
as HDL and LDL cholesterol present minor changes dur-
ing the dialysis cycle. A slight increase of triglycerides was
observed, due probably to the feeding of subjects during
hemodialysis.
Total and corrected plasma antioxidant capacity during 
dialysis
Figure 2 presents the variation of TAC during dialysis, in
the ten hemodialyzed patients. As expected, due to the
presence of a number of endogenous metabolites dotted
with antioxidant activity (for example uric acid) initial
TAC values of hemodialyzed patients are high, as com-
pared to those of control individuals. During dialysis
however, these elevated values decrease, according to an
exponential decay model, with t1/2 of 24.8 min. Thereaf-
ter, they remain constant during the whole time of
dialysis.
Corrected TAC is also depicted in Figure 2. As stated in our
previous work [33], this calculated parameter represents
the fraction of circulating antioxidants, after the elimina-
tion of interference of endogenous metabolites. Our pre-
vious work has shown that uric acid and bilirubin, and to
a lesser degree albumin, are the major analytes interfering
linearly with coefficients of 0.11, 0.11 and 0.01 mmol/L
of TAC per mg/dL of each analyte respectively. We have
therefore calculated the corrected TAC values in the same
patients. As shown, corrected TAC increases during the
dialysis procedure, following a sigmoidal curve, with t1/2
of 174 min. It is interesting to note that this value is
slightly higher from the t1/2 of uric acid decay (174 ± 14.1
min, as compared to 101.2 ± 12.8 min respectively).
Comparing TAC and corrected TAC values with those
obtained in normal blood donors (depicted in Figure 2 as
up and down triangles respectively), it is observed that
total TAC values are significantly decreased (t = 3.75, p <
0.001) in hemodialyzed patients as compared to controls.
In contrast, while initial corrected TAC values are signifi-
cantly lower than those of controls (t = 2.97, p < 0.01),
they reach normal values at the end of dialysis.
Effect of different dialysis filters on metabolites and TAC 
values
Previous works have suggested that hemodialysis-related
oxidative burden relies greatly on the dialysis membrane
used. In this respect, as antioxidants might be consumed
during a surge of oxidative molecules, TAC (as well as cor-
rected TAC) might be decreased with the use of different
membranes. We therefore attempted to investigate the
effect of filters on TAC and corrected TAC values, in 65
patients (33 males and 32 females). Thirty-six patients
were dialyzed using an ethylene vinyl alcohol copolymer
resin (Eval) filter. In 10 and 13 patients, F6 and PSN140
polysulfone filters were used, respectively. Finally, 6
patients were dialyzed using a GFS12+ hemophan filter.
The obtained results are presented in Figure 3. As shown,
no significant differences were observed in any group
(Kruskal-Wallis test statistics with p > 0.05 in any case),
indicating that at least the filters used in the present study
do not modify drastically the redox state of patients, dur-
ing the dialysis procedure.
Discussion
The primary defense against oxidative stress in extracellu-
lar fluids results from a number of low molecular weight
antioxidant molecules being either water- (ex. ascorbic
acid) or lipid-soluble (ex. Vitamin E). These antioxidants
are either generated during normal metabolism (ex. uricBMC Nephrology 2003, 4 http://www.biomedcentral.com/1471-2369/4/4
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acid, bilirubin, albumin, thiols) or introduced in the body
by the consumption of dietary products rich in antioxi-
dants (olive oil, fruits and vegetables, tea, wine, etc) [34].
The sum of endogenous plus exogenous (food-derived)
antioxidants represents the total antioxidant capacity of
extracellular fluids. Changes of these antioxidants reflect
their consumption during acute oxidative stress states. It
should be noted that cooperation between different anti-
oxidant pathways provides greater protection against
attack by reactive oxygen or nitrogen radicals, compared
to any single compound. Thus, the overall antioxidant
capacity may give more relevant biological information
compared to that obtained by the measurement of indi-
vidual biomarkers, as it considers the cumulative effect of
all antioxidants present in plasma and body fluids [35]. A
theory has recently been proposed, taking into account
the redox potentials of exogenous and endogenous anti-
oxidants. It postulates a cascade of reactions, in which fol-
lowing an oxidative stress, a lesser antioxidant is
generated from a more potent one. Through this cascade,
interactions among the lipid and the aqueous phases
could be established [36].
A great variety of methods have been proposed for the
assay of total antioxidant activity or capacity of serum or
plasma [reviewed extensively and critically in [34,35]].
They stress the fine distinction between antioxidant activ-
ity  and antioxidant capacity:  Antioxidant activity corre-
sponds to the rate constant of a single antioxidant against
a given free radical; a ntioxidant capacity, on the other
hand, is the number of moles of a given free radical scav-
enged by a test solution, independently of the capacity of
any one antioxidant present in the mixture [35]. In the
case of plasma, being a heterogeneous solution of diverse
Variation of uric acid, albumin, hematocrit, bilirubin and lipids during dialysis. Data obtained from 10 dialysis patients Figure 1
Variation of uric acid, albumin, hematocrit, bilirubin and lipids during dialysis Data obtained from 10 dialysis patients. Mean ± SEM are 
depicted.
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antioxidants, the antioxidant status is better reflected by
antioxidant capacity rather than activity alone. This
capacity is a combination of all redox chain antioxidants,
including several analytes such as thiol bearing proteins,
and uric acid. It thus appears that plasma antioxidant
capacity is rather a concept than a simple analytical deter-
mination. Indeed, an increase of antioxidant capacity of
plasma indicates absorption of antioxidants and
improved in vivo antioxidant status [37], or the result of
the activation of an adaptation mechanism to oxidative
stress. It should be noted that, due to the contribution of
diverse metabolites to the antioxidant capacity of human
plasma, its increase may not necessarily be a desirable
condition. Indeed, in some cases, such as renal failure
(uric acid), icteric status (bilirubin), hepatic damage
(hypoalbuminemia) the increase or decrease of several
metabolites modifies plasma antioxidant capacity, a situ-
ation returning to physiological values after correction of
the underlying disease [38]. In addition, high concentra-
tion of a number of metabolites, including uric acid, can
lead to prooxidant effects, introducing a further decrease
of the plasma antioxidant capacity [11]. Recently, we have
introduced a new automated method for the assay of the
plasma antioxidant capacity, based on the bleaching of
crocin. This method (the TAC assay) gives an estimation
of the integrated plasma antioxidant capacity. Further-
more, we also determined the interference of a number of
endogenous analytes, such as uric acid, and bilirubin,
which have been found to produce a major interference of
TAC, while albumin results in a smaller interference [33].
The subtraction of these interferences in TAC assay
resulted in the calculation of corrected TAC, cTAC repre-
senting the amount of antioxidant capacity due to the
action of (mainly) exogenous antioxidants.
In the present work, we have assayed simultaneously TAC
and the concentrations of these analytes during a single
episode of hemodialysis. Although uremic plasma is
almost unique in its concentration of numberless metab-
olites and toxins, identified or unknown, measurable or
not, the concept of the TAC assay, measuring the inhibi-
tion of an exogenously added oxidant makes the assay
suitable for the identification of the antioxidant capacity
of uremic plasma. Concerning cTAC, we are aware that the
subtraction of the interaction of albumin, bilirubin and
uric acid only, may not take into account other (known or
Variations of TAC and corrected TAC during dialysis. Up and  down arrows depict values obtained in normal blood donors Figure 2
Variations of TAC and corrected TAC during dialysis Up and 
down arrows depict values obtained in normal blood donors. 
Mean ± SEM of 10 patients and 56 blood donors
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unknown) endogenous metabolites and toxins with a
proper antioxidant or prooxidant activity. Therefore, the
results concerning the cTAC measurements must be con-
sidered as indicative. In addition, a number of medica-
tions may influence the plasma antioxidant capacity.
Nevertheless, an almost similar medication regime was
followed by the parients' group. Therefore, the effect of
medication (if any) on the results of the TAC assay, may
be considered as constant.
Major modifications of a number of endogenous metabo-
lites were observed during dialysis. Namely, uric acid is
rapidly eliminated, with t1/2 of 101 min (Figure 1), while
albumin plasma concentration is increased (t1/2 21 min)
probably due to the hemoconcentration during dialysis.
Bilirubin, on the other hand, follows a biphasic pattern
with an initial decrease (possibly due to elimination) fol-
lowed by an increase due to hemoconcentration. Lipids
do not present major variations during the dialysis epi-
sode studied, with the exception of triglycerides due to the
feeding of patients. As significant changes were not
observed, the implication of lipids on the TAC assay was
omitted. Total TAC measurements present equally major
changes, following those of the above analytes. Indeed,
results presented in Figure 2 show that the plasma antioxi-
dant capacity of patients is higher before than during or
after a session of dialysis. This can be due to the elimina-
tion of a number of metabolites, such as uric acid and
bilirubin (Figure 1). In this respect our results are similar
to those presented in previous reports, in which a compa-
rable decrease of plasma antioxidant capacity was
observed during renal dialysis [2,3,8–10,15,26,32,39,40].
Total TAC was found to increase later in hemodialysis,
most probably due to either hemoconcentration [31],
adaptation [41], or to a possible exchange of antioxidants
between the lipid and aqueous phases [36]. Whether urate
by itself and other analytes, at the concentrations encoun-
tered in dialysis patients and in the milieu of uremic
plasma, exert a pro-oxidant [11] or antioxidant effect
remains a matter of debate.
Calculation of the corrected TAC appears to provide a bet-
ter estimate of the actual antioxidant activity of the organ-
ism, especially in cases such as renal dialysis, in which
major fluctuations of endogenous metabolites and the
elimination of a number of toxins occur. Indeed, as
shown in Figure 2, the curve of corrected TAC is different
from that of TAC. Specifically, a gradual increase of
plasma antioxidant capacity is observed, with t1/2 of about
30 min. Various explanations for these results could be
proposed: (1) Water elimination during dialysis causes
increased concentration of endogenous antioxidant sub-
stances [31]. (2) Elimination of uric acid modifies the
equilibrium between oxidized and reduced states of
endogenous and exogenous antioxidants [41,42]. (3) It
has been recently proposed that elimination of water-sol-
uble metabolic antioxidants (bilirubin, uric acid) modi-
fies the equilibrium of lipid- and water-soluble
antioxidants [36]. (4) The presumed "antioxidant effect"
of hemodialysis, detected here by cTAC, has also been
attributed to the plasma glutathione increase by hemodi-
alysis [25,43,44].
Redox state in uremic patients undergoing dialysis is
rather confused. Several reports provide possible patho-
physiological explanations of the observed changes in
redox state and antioxidant status. It appears that patients
with malnutrition and a low plasma albumin concentra-
tion have significantly reduced plasma antioxidant capac-
ity due to the diminished availability of thiol groups [45].
Serologic evidence of an activated inflammatory response
has been reported [46], as well as the contribution of
phagocytes and cytokines to increased production of ROS
[47–50]. Several lines of evidence indicate that further
oxidative modification of retained solutes in the uremic
milieu (ex. β2 microglobulin, homocysteine, cysteine)
may potentiate their pathogenicity [51–53]. Dialytic ther-
apy, which acts to reduce the concentration of oxidized
substrates, improves the redox balance [12,54]. However,
processes related to repetitive extracorporeal dialytic ther-
apies (prolonged use of catheters for vascular access, use
of bioincompatible dialysis membranes) can incite fur-
ther inflammatory and oxidative stimuli (via complement
and leukocyte activation), thus contributing to a pro-
atherogenic state [55,56].
Our data, presented in Figure 3 indicate that no major
changes in both analytes and TAC are observed with the
use of modern filters. It has already been reported that
hemodialysis decreases the oxidation levels of plasma
protein-associated thiol groups [51]. It would be of inter-
est to measure TAC and cTAC in patients dialyzed with
vitamin E-modified membranes. It should be noted, how-
ever, that even with the use of vitamin E-modified filters,
results on oxidative stress markers can be confounding.
In conclusion, our data suggest that although during
hemodialysis several factors contribute to the generation
of oxidative radicals, the organism is able to successfully
resist the flood of oxidative substances. Oxidation and
peroxidation reactions of renal failure patients must be
reevaluated under this point of view, taking into account
the auto-oxidation of excess antioxidants, as was recently
reported for vitamin C and tocopherols [57–60], rather
than a decrease of the plasma antioxidant capacity. Never-
theless, more extensive studies must be performed, taking
into acoount the possible abrupt change of the plasma
oxidative status at the end of dialysis, or the hours follow-
ing it [12].BMC Nephrology 2003, 4 http://www.biomedcentral.com/1471-2369/4/4
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